マウスモデル作製市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

当レポートでは、世界のマウスモデル作製市場について調査し、市場の概要とともに、2022年～2031年の予測、技術別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界のマウスモデル作製市場

第4章 市場概要

• イントロダクション
• 概要
• 市場力学
• 世界のマウスモデル作製市場の分析と予測、2017年～2031年

第5章 主な洞察

第6章 世界のマウスモデル作製市場分析と予測、技術別

• イントロダクションと定義
• 主な調査結果/開発
• 技術別市場価値予測、2017年～2031年
  • CRISPRノックアウト
  • CRISPRノックイン
  • ランダム挿入
  • 大型、標的挿入
  • ES細胞改変（相同組換え）
  • その他
• 技術別の市場魅力分析

第7章 世界のマウスモデル作製市場分析と予測、エンドユーザー別

• イントロダクションと定義
• 主な調査結果/開発
• 市場価値予測、エンドユーザー別、2017年～2031年
  • 製薬会社
  • バイオテクノロジー企業
  • 学術・研究施設
  • 受託研究・製造機関
• エンドユーザー別の市場魅力分析

第8章 世界のマウスモデル作製市場分析と予測、地域別

• 主な調査結果
• 地域別市場価値予測
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
• 地域別の市場魅力分析

第9章 北米のマウスモデル作製市場分析と予測

第10章 欧州のマウスモデル作製市場の分析と予測

第11章 アジア太平洋のマウスモデル作製市場分析と予測

第12章 ラテンアメリカのマウスモデル作製市場分析と予測

第13章 中東・アフリカのマウスモデル作製市場分析と予測

第14章 競合情勢

• 市場参入企業 - 競合マトリクス（層および企業規模別）
• 市場シェア分析、企業別、2021年
• 企業プロファイル
  • Biocytogen
  • Charles River Laboratories
  • Cyagen Biosciences
  • Gempharmatech
  • genOway
  • ingenious targeting laboratory
  • Merck KGaA
  • Ozgene Pty Ltd.
  • Taconic Biosciences, Inc.
  • PolyGene AG
  • The Jackson Laboratory
  • Yale School of Medicine
  • University of North Carolina
  • University of Nebraska Medical Center
  • Monash University
  • UMass Chan Medical School
  • University of Bonn
  • Columbia University
  • The University of Arizona
  • Hadassah BrainLabs
  • The Weizmann Institute of Science
  • The Hebrew University of Jerusalem
  • The Technion-Israel Institute of Technology

List of Tables

• Table 01: Price/Cost Analysis of Mice Models, by Region
• Table 02: Global Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 03: Global Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 04: Global Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 05: Global Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 06: Global Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017-2031
• Table 07: Global Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017-2031
• Table 08: Global Mice Model Generation Market Value (US$ Mn) Forecast, by Region, 2017-2031
• Table 09: North America Mice Model Generation Market Value (US$ Mn) Forecast, by Country, 2017-2031
• Table 10: North America Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 11: North America Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 12: North America Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 13: North America Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 14: North America Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017-2031
• Table 15: North America Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017-2031
• Table 16: Europe Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 17: Europe Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 18: Europe Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 19: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 20: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 21: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017-2031
• Table 22: Europe Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017-2031
• Table 23: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 24: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 25: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 26: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 27: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 28: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017-2031
• Table 29: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017-2031
• Table 30: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 31: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 32: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 33: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 34: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 35: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017-2031
• Table 36: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017-2031
• Table 37: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
• Table 38: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, by Technology, 2017-2031
• Table 39: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, by End-user, 2017-2031
• Table 40: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
• Table 41: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
• Table 42: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017-2031
• Table 43: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, Contract Research & Manufacturing Organizations by Technology, 2017-2031

List of Figures

• Figure 01: Global Mice Model Generation Market Value (US$ Mn) Forecast, 2017-2031
• Figure 02: Global Mice Model Generation Market Value Share, by Technology, 2021
• Figure 03: Global Mice Model Generation Market Value Share, by End-user, 2021
• Figure 04: Global Mice Model Generation Market Value Share, by Region, 2021
• Figure 05: Global Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 06: Global Mice Model Generation Market Attractiveness Analysis, by Technology, 2022-2031
• Figure 07: Global Mice Model Generation Market Value (US$ Mn), by CRISPR Knockout, 2017-2031
• Figure 08: Global Mice Model Generation Market Value (US$ Mn), by CRISPR Knockin Mice, 2017-2031
• Figure 09: Global Mice Model Generation Market Value (US$ Mn), by Random Insertions, 2017-2031
• Figure 10: Global Mice Model Generation Market Value (US$ Mn), by Large, Targeted Insertions, 2017-2031
• Figure 11: Global Mice Model Generation Market Value (US$ Mn), by ES Cell Modification (homologous recombination), 2017-2031
• Figure 12: Global Mice Model Generation Market Value (US$ Mn), by Others, 2017-2031
• Figure 13: Global Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 14: Global Mice Model Generation Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 15: Global Mice Model Generation Market Value (US$ Mn), by Pharmaceutical Companies, 2017-2031
• Figure 16: Global Mice Model Generation Market Value (US$ Mn), by Biotechnology Companies, 2017-2031
• Figure 17: Global Mice Model Generation Market Value (US$ Mn), by Academic & Research Facilities, 2017-2031
• Figure 18: Global Mice Model Generation Market Value (US$ Mn), by Contract Research & Manufacturing Organizations, 2017-2031
• Figure 19: Global Mice Model Generation Market Value Share Analysis, by Region, 2021 and 2031
• Figure 20: Global Mice Model Generation Market Attractiveness Analysis, by Region, 2022-2031
• Figure 21: North America Mice Model Generation Market Value (US$ Mn) Forecast, 2017-2031
• Figure 23: North America Mice Model Generation Market Attractiveness Analysis, by Country, 2022-2031
• Figure 22: North America Mice Model Generation Market Value Share Analysis, by Country, 2021 and 2031
• Figure 24: North America Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 25: North America Mice Model Generation Market Attractiveness Analysis, by Technology, 2022-2031
• Figure 26: North America Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 27: North America Mice Model Generation Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 28: Europe Mice Model Generation Market Value (US$ Mn) Forecast, 2017-2031
• Figure 30: Europe Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 29: Europe Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
• Figure 31: Europe Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 32: Europe Mice Model Generation Market Attractiveness Analysis, by Technology, 2022-2031
• Figure 33: Europe Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 34: Europe Mice Model Generation Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 35: Asia Pacific Mice Model Generation Market Value (US$ Mn) Forecast, 2017-2031
• Figure 37: Asia Pacific Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
• Figure 36: Asia Pacific Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
• Figure 38: Asia Pacific Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 39: Asia Pacific Mice Model Generation Market Attractiveness Index, by Technology, 2022-2031
• Figure 40: Asia Pacific Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 41: Asia Pacific Mice Model Generation Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 42: Latin America Mice Model Generation Market Value (US$ Mn) Forecast, 2017-2031
• Figure 44: Latin America Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
• Figure 43: Latin America Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
• Figure 45: Latin America Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 46: Latin America Mice Model Generation Market Attractiveness Analysis, by Technology, 2022-2031
• Figure 47: Latin America Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 48: Latin America Mice Model Generation Market Attractiveness Analysis, by End-user, 2022-2031
• Figure 49: Middle East & Africa Mice Model Generation Market Value (US$ Mn) Forecast, 2017-2031
• Figure 51: Middle East & Africa Mice Model Generation Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
• Figure 50: Middle East & Africa Mice Model Generation Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
• Figure 52: Middle East & Africa Mice Model Generation Market Value Share Analysis, by Technology, 2021 and 2031
• Figure 53: Middle East & Africa Mice Model Generation Market Attractiveness Analysis, by Technology, 2022-2031
• Figure 54: Middle East & Africa Mice Model Generation Market Value Share Analysis, by End-user, 2021 and 2031
• Figure 55: Middle East & Africa Mice Model Generation Market Attractiveness Analysis, by End-user, 2022-2031

TMR's report on the global mice model generation market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global mice model generation market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global mice model generation market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the mice model generation market.

The report delves into the competitive landscape of the global mice model generation market. Key players operating in the global mice model generation market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global mice model generation market profiled in this report.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Mice Model Generation Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Mice Model Generation Market Analysis and Forecast, 2017-2031
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Global Genetically Engineered Mouse Model Overview
• 5.2. Regulatory Scenario by Region/globally
• 5.3. Technological Advancements
• 5.4. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
• 5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Mice Model Generation Market Analysis and Forecast, by Technology

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Technology, 2017-2031
  • 6.3.1. CRISPR Knockout
  • 6.3.2. CRISPR Knockin
  • 6.3.3. Random Insertions
  • 6.3.4. Large, Targeted Insertions
  • 6.3.5. ES Cell Modification (homologous recombination)
  • 6.3.6. Others
• 6.4. Market Attractiveness Analysis, by Technology

7. Global Mice Model Generation Market Analysis and Forecast, by End-user

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by End-user, 2017-2031
  • 7.3.1. Pharmaceutical Companies
  • 7.3.2. Biotechnology Companies
  • 7.3.3. Academic & Research Facilities
  • 7.3.4. Contract Research & Manufacturing Organizations
• 7.4. Market Attractiveness Analysis, by End-user

8. Global Mice Model Generation Market Analysis and Forecast, by Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Region
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness Analysis, by Region

9. North America Mice Model Generation Market Analysis and Forecast

• 9.1. Introduction
  • 9.1.1. Key Findings
• 9.2. Market Value Forecast, by Technology, 2017-2031
  • 9.2.1. CRISPR Knockout
  • 9.2.2. CRISPR Knockin
  • 9.2.3. Random Insertions
  • 9.2.4. Large, Targeted Insertions
  • 9.2.5. ES Cell Modification (homologous recombination)
  • 9.2.6. Others
• 9.3. Market Value Forecast, by End-user, 2017-2031
  • 9.3.1. Pharmaceutical Companies
  • 9.3.2. Biotechnology Companies
  • 9.3.3. Academic & Research Facilities
  • 9.3.4. Contract Research & Manufacturing Organizations
• 9.4. Market Value Forecast, by End-user by Technology, 2017-2031
  • 9.4.1. Pharmaceutical Companies
    • 9.4.1.1. CRISPR Knockout
    • 9.4.1.2. CRISPR Knockin
    • 9.4.1.3. Random Insertions
    • 9.4.1.4. Large, Targeted Insertions
    • 9.4.1.5. ES Cell Modification (homologous recombination)
    • 9.4.1.6. Others
  • 9.4.2. Biotechnology Companies
    • 9.4.2.1. CRISPR Knockout
    • 9.4.2.2. CRISPR Knockin
    • 9.4.2.3. Random Insertions
    • 9.4.2.4. Large, Targeted Insertions
    • 9.4.2.5. ES Cell Modification (homologous recombination)
    • 9.4.2.6. Others
  • 9.4.3. Academic & Research Facilities
    • 9.4.3.1. CRISPR Knockout
    • 9.4.3.2. CRISPR Knockin
    • 9.4.3.3. Random Insertions
    • 9.4.3.4. Large, Targeted Insertions
    • 9.4.3.5. ES Cell Modification (homologous recombination)
    • 9.4.3.6. Others
  • 9.4.4. Contract Research & Manufacturing Organizations
    • 9.4.4.1. CRISPR Knockout
    • 9.4.4.2. CRISPR Knockin
    • 9.4.4.3. Random Insertions
    • 9.4.4.4. Large, Targeted Insertions
    • 9.4.4.5. ES Cell Modification (homologous recombination)
    • 9.4.4.6. Others
• 9.5. Market Value Forecast, by Country, 2017-2031
  • 9.5.1. U.S.
  • 9.5.2. Canada
• 9.6. Market Attractiveness Analysis
  • 9.6.1. By Technology
  • 9.6.2. By End-user
  • 9.6.3. By End-user by Technology
  • 9.6.4. By Country

10. Europe Mice Model Generation Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Technology, 2017-2031
  • 10.2.1. CRISPR Knockout
  • 10.2.2. CRISPR Knockin
  • 10.2.3. Random Insertions
  • 10.2.4. Large, Targeted Insertions
  • 10.2.5. ES Cell Modification (homologous recombination)
  • 10.2.6. Others
• 10.3. Market Value Forecast, by End-user, 2017-2031
  • 10.3.1. Pharmaceutical Companies
  • 10.3.2. Biotechnology Companies
  • 10.3.3. Academic & Research Facilities
  • 10.3.4. Contract Research & Manufacturing Organizations
• 10.4. Market Value Forecast, by End-user by Technology, 2017-2031
  • 10.4.1. Pharmaceutical Companies
    • 10.4.1.1. CRISPR Knockout
    • 10.4.1.2. CRISPR Knockin
    • 10.4.1.3. Random Insertions
    • 10.4.1.4. Large, Targeted Insertions
    • 10.4.1.5. ES Cell Modification (homologous recombination)
    • 10.4.1.6. Others
  • 10.4.2. Biotechnology Companies
    • 10.4.2.1. CRISPR Knockout
    • 10.4.2.2. CRISPR Knockin
    • 10.4.2.3. Random Insertions
    • 10.4.2.4. Large, Targeted Insertions
    • 10.4.2.5. ES Cell Modification (homologous recombination)
    • 10.4.2.6. Others
  • 10.4.3. Academic & Research Facilities
    • 10.4.3.1. CRISPR Knockout
    • 10.4.3.2. CRISPR Knockin
    • 10.4.3.3. Random Insertions
    • 10.4.3.4. Large, Targeted Insertions
    • 10.4.3.5. ES Cell Modification (homologous recombination)
    • 10.4.3.6. Others
  • 10.4.4. Contract Research & Manufacturing Organizations
    • 10.4.4.1. CRISPR Knockout
    • 10.4.4.2. CRISPR Knockin
    • 10.4.4.3. Random Insertions
    • 10.4.4.4. Large, Targeted Insertions
    • 10.4.4.5. ES Cell Modification (homologous recombination)
    • 10.4.4.6. Others
• 10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 10.5.1. Germany
  • 10.5.2. U.K.
  • 10.5.3. France
  • 10.5.4. Spain
  • 10.5.5. Italy
  • 10.5.6. Rest of Europe
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Technology
  • 10.6.2. By End-user
  • 10.6.3. By End-user by Technology
  • 10.6.4. By Country/Sub-region

11. Asia Pacific Mice Model Generation Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Technology, 2017-2031
  • 11.2.1. CRISPR Knockout
  • 11.2.2. CRISPR Knockin
  • 11.2.3. Random Insertions
  • 11.2.4. Large, Targeted Insertions
  • 11.2.5. ES Cell Modification (homologous recombination)
  • 11.2.6. Others
• 11.3. Market Value Forecast, by End-user, 2017-2031
  • 11.3.1. Pharmaceutical Companies
  • 11.3.2. Biotechnology Companies
  • 11.3.3. Academic & Research Facilities
  • 11.3.4. Contract Research & Manufacturing Organizations
• 11.4. Market Value Forecast, by End-user by Technology, 2017-2031
  • 11.4.1. Pharmaceutical Companies
    • 11.4.1.1. CRISPR Knockout
    • 11.4.1.2. CRISPR Knockin
    • 11.4.1.3. Random Insertions
    • 11.4.1.4. Large, Targeted Insertions
    • 11.4.1.5. ES Cell Modification (homologous recombination)
    • 11.4.1.6. Others
  • 11.4.2. Biotechnology Companies
    • 11.4.2.1. CRISPR Knockout
    • 11.4.2.2. CRISPR Knockin
    • 11.4.2.3. Random Insertions
    • 11.4.2.4. Large, Targeted Insertions
    • 11.4.2.5. ES Cell Modification (homologous recombination)
    • 11.4.2.6. Others
  • 11.4.3. Academic & Research Facilities
    • 11.4.3.1. CRISPR Knockout
    • 11.4.3.2. CRISPR Knockin
    • 11.4.3.3. Random Insertions
    • 11.4.3.4. Large, Targeted Insertions
    • 11.4.3.5. ES Cell Modification (homologous recombination)
    • 11.4.3.6. Others
  • 11.4.4. Contract Research & Manufacturing Organizations
    • 11.4.4.1. CRISPR Knockout
    • 11.4.4.2. CRISPR Knockin
    • 11.4.4.3. Random Insertions
    • 11.4.4.4. Large, Targeted Insertions
    • 11.4.4.5. ES Cell Modification (homologous recombination)
    • 11.4.4.6. Others
• 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.5.1. China
  • 11.5.2. Japan
  • 11.5.3. India
  • 11.5.4. Australia & New Zealand
  • 11.5.5. Rest of Asia Pacific
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Technology
  • 11.6.2. By End-user
  • 11.6.3. By End-user by Technology
  • 11.6.4. By Country/Sub-region

12. Latin America Mice Model Generation Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Technology, 2017-2031
  • 12.2.1. CRISPR Knockout
  • 12.2.2. CRISPR Knockin
  • 12.2.3. Random Insertions
  • 12.2.4. Large, Targeted Insertions
  • 12.2.5. ES Cell Modification (homologous recombination)
  • 12.2.6. Others
• 12.3. Market Value Forecast, by End-user, 2017-2031
  • 12.3.1. Pharmaceutical Companies
  • 12.3.2. Biotechnology Companies
  • 12.3.3. Academic & Research Facilities
  • 12.3.4. Contract Research & Manufacturing Organizations
• 12.4. Market Value Forecast, by End-user by Technology, 2017-2031
  • 12.4.1. Pharmaceutical Companies
    • 12.4.1.1. CRISPR Knockout
    • 12.4.1.2. CRISPR Knockin
    • 12.4.1.3. Random Insertions
    • 12.4.1.4. Large, Targeted Insertions
    • 12.4.1.5. ES Cell Modification (homologous recombination)
    • 12.4.1.6. Others
  • 12.4.2. Biotechnology Companies
    • 12.4.2.1. CRISPR Knockout
    • 12.4.2.2. CRISPR Knockin
    • 12.4.2.3. Random Insertions
    • 12.4.2.4. Large, Targeted Insertions
    • 12.4.2.5. ES Cell Modification (homologous recombination)
    • 12.4.2.6. Others
  • 12.4.3. Academic & Research Facilities
    • 12.4.3.1. CRISPR Knockout
    • 12.4.3.2. CRISPR Knockin
    • 12.4.3.3. Random Insertions
    • 12.4.3.4. Large, Targeted Insertions
    • 12.4.3.5. ES Cell Modification (homologous recombination)
    • 12.4.3.6. Others
  • 12.4.4. Contract Research & Manufacturing Organizations
    • 12.4.4.1. CRISPR Knockout
    • 12.4.4.2. CRISPR Knockin
    • 12.4.4.3. Random Insertions
    • 12.4.4.4. Large, Targeted Insertions
    • 12.4.4.5. ES Cell Modification (homologous recombination)
    • 12.4.4.6. Others
• 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.5.1. Brazil
  • 12.5.2. Mexico
  • 12.5.3. Rest of Latin America
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Technology
  • 12.6.2. By End-user
  • 12.6.3. By End-user by Technology
  • 12.6.4. By Country/Sub-region

13. Middle East & Africa Mice Model Generation Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Technology, 2017-2031
  • 13.2.1. CRISPR Knockout
  • 13.2.2. CRISPR Knockin
  • 13.2.3. Random Insertions
  • 13.2.4. Large, Targeted Insertions
  • 13.2.5. ES Cell Modification (homologous recombination)
  • 13.2.6. Others
• 13.3. Market Value Forecast, by End-user, 2017-2031
  • 13.3.1. Pharmaceutical Companies
  • 13.3.2. Biotechnology Companies
  • 13.3.3. Academic & Research Facilities
  • 13.3.4. Contract Research & Manufacturing Organizations
• 13.4. Market Value Forecast, by End-user by Technology, 2017-2031
  • 13.4.1. Pharmaceutical Companies
    • 13.4.1.1. CRISPR Knockout
    • 13.4.1.2. CRISPR Knockin
    • 13.4.1.3. Random Insertions
    • 13.4.1.4. Large, Targeted Insertions
    • 13.4.1.5. ES Cell Modification (homologous recombination)
    • 13.4.1.6. Others
  • 13.4.2. Biotechnology Companies
    • 13.4.2.1. CRISPR Knockout
    • 13.4.2.2. CRISPR Knockin
    • 13.4.2.3. Random Insertions
    • 13.4.2.4. Large, Targeted Insertions
    • 13.4.2.5. ES Cell Modification (homologous recombination)
    • 13.4.2.6. Others
  • 13.4.3. Academic & Research Facilities
    • 13.4.3.1. CRISPR Knockout
    • 13.4.3.2. CRISPR Knockin
    • 13.4.3.3. Random Insertions
    • 13.4.3.4. Large, Targeted Insertions
    • 13.4.3.5. ES Cell Modification (homologous recombination)
    • 13.4.3.6. Others
  • 13.4.4. Contract Research & Manufacturing Organizations
    • 13.4.4.1. CRISPR Knockout
    • 13.4.4.2. CRISPR Knockin
    • 13.4.4.3. Random Insertions
    • 13.4.4.4. Large, Targeted Insertions
    • 13.4.4.5. ES Cell Modification (homologous recombination)
    • 13.4.4.6. Others
• 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.5.1. GCC Countries
  • 13.5.2. South Africa
  • 13.5.3. Rest of Middle East & Africa
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Technology
  • 13.6.2. By End-user
  • 13.6.3. By End-user by Technology
  • 13.6.4. By Country/Sub-region

14. Competition Landscape

• 14.1. Market Player - Competition Matrix (by tier and size of companies)
• 14.2. Market Share Analysis, by Company, 2021
  • 14.2.1. Global
  • 14.2.2. North America
  • 14.2.3. Europe
  • 14.2.4. By Asia Pacific
  • 14.2.5. By Latin America
  • 14.2.6. By Middle East & Africa
• 14.3. Company Profiles
  • 14.3.1. Biocytogen
    • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.1.2. Product Portfolio
    • 14.3.1.3. SWOT Analysis
    • 14.3.1.4. Strategic Overview
  • 14.3.2. Charles River Laboratories
    • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.2.2. Product Portfolio
    • 14.3.2.3. SWOT Analysis
    • 14.3.2.4. Strategic Overview
  • 14.3.3. Cyagen Biosciences
    • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.3.2. Product Portfolio
    • 14.3.3.3. SWOT Analysis
    • 14.3.3.4. Strategic Overview
  • 14.3.4. Gempharmatech
    • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.4.2. Product Portfolio
    • 14.3.4.3. SWOT Analysis
    • 14.3.4.4. Strategic Overview
  • 14.3.5. genOway
    • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.5.2. Product Portfolio
    • 14.3.5.3. SWOT Analysis
    • 14.3.5.4. Strategic Overview
  • 14.3.6. ingenious targeting laboratory
    • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.6.2. Product Portfolio
    • 14.3.6.3. SWOT Analysis
    • 14.3.6.4. Strategic Overview
  • 14.3.7. Merck KGaA
    • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.7.2. Product Portfolio
    • 14.3.7.3. SWOT Analysis
    • 14.3.7.4. Strategic Overview
  • 14.3.8. Ozgene Pty Ltd.
    • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.8.2. Product Portfolio
    • 14.3.8.3. SWOT Analysis
    • 14.3.8.4. Strategic Overview
  • 14.3.9. Taconic Biosciences, Inc.
    • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.9.2. Product Portfolio
    • 14.3.9.3. SWOT Analysis
    • 14.3.9.4. Strategic Overview
  • 14.3.10. PolyGene AG
    • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.10.2. Product Portfolio
    • 14.3.10.3. SWOT Analysis
    • 14.3.10.4. Strategic Overview
  • 14.3.11. The Jackson Laboratory
    • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.11.2. Product Portfolio
    • 14.3.11.3. SWOT Analysis
    • 14.3.11.4. Strategic Overview
  • 14.3.12. Yale School of Medicine
    • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.12.2. Product Portfolio
    • 14.3.12.3. SWOT Analysis
    • 14.3.12.4. Strategic Overview
  • 14.3.13. University of North Carolina
    • 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.13.2. Product Portfolio
    • 14.3.13.3. SWOT Analysis
    • 14.3.13.4. Strategic Overview
  • 14.3.14. University of Nebraska Medical Center
    • 14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.14.2. Product Portfolio
    • 14.3.14.3. SWOT Analysis
    • 14.3.14.4. Strategic Overview
  • 14.3.15. Monash University
    • 14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.15.2. Product Portfolio
    • 14.3.15.3. SWOT Analysis
    • 14.3.15.4. Strategic Overview
  • 14.3.16. UMass Chan Medical School
    • 14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.16.2. Product Portfolio
    • 14.3.16.3. SWOT Analysis
    • 14.3.16.4. Strategic Overview
  • 14.3.17. University of Bonn
    • 14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.17.2. Product Portfolio
    • 14.3.17.3. SWOT Analysis
    • 14.3.17.4. Strategic Overview
  • 14.3.18. Columbia University
    • 14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.18.2. Product Portfolio
    • 14.3.18.3. SWOT Analysis
    • 14.3.18.4. Strategic Overview
  • 14.3.19. The University of Arizona
    • 14.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.19.2. Product Portfolio
    • 14.3.19.3. SWOT Analysis
    • 14.3.19.4. Strategic Overview
  • 14.3.20. Hadassah BrainLabs
    • 14.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.20.2. Product Portfolio
    • 14.3.20.3. SWOT Analysis
    • 14.3.20.4. Strategic Overview
  • 14.3.21. The Weizmann Institute of Science
    • 14.3.21.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.21.2. Product Portfolio
    • 14.3.21.3. SWOT Analysis
    • 14.3.21.4. Strategic Overview
  • 14.3.22. The Hebrew University of Jerusalem
    • 14.3.22.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.22.2. Product Portfolio
    • 14.3.22.3. SWOT Analysis
    • 14.3.22.4. Strategic Overview
  • 14.3.23. The Technion - Israel Institute of Technology
    • 14.3.23.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 14.3.23.2. Product Portfolio
    • 14.3.23.3. SWOT Analysis
    • 14.3.23.4. Strategic Overview